Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques.

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the United States and is projected to be the second by 2030. Systemic combination chemotherapy is considered an essential first-line treatment for the majority of patients with PDA, in both the neoadjuvant and palliative settings. In addition, a number of novel therapies are being tested in clinical trials for patients with advanced PDA. In all cases, accurate and timely assessment of treatment response is critical to guide therapy, reduce drug toxicities and cost from a failing therapy, and aid adaptive clinical trials. Conventional morphological imaging has significant limitations, especially in the context of determining primary tumor response and resectability following neoadjuvant therapies. In this article, we provide an overview of current therapy options for PDA, highlight several morphological imaging findings that may be helpful to reduce over-staging following neoadjuvant therapy, and discuss a number of emerging imaging, and non-imaging, tools that have shown promise in providing a more precise quantification of disease burden and treatment response in PDA.

• Authors: Zhen J Wang, Hina Arif-Tiwari, Atif Zaheer, Sanaz Ameli, Priya R Bhosale, Richard K Do, Ajit H Goenka, Alexander R Guimares, Guillermo P Sangster, Erik V Soloff, Eric P Tamm, Marc Zins, Avinash R Kambadakone
• Journal: Abdominal radiology (New York) (Abdom Radiol (NY)) Vol. 45 Issue 12 Pg. 4273-4289 (12 2020) ISSN: 2366-0058 [Electronic] United States
• PMID: 32936417 (Publication Type: Journal Article, Review)

Topics

• Adenocarcinoma
• Carcinoma, Pancreatic Ductal (diagnostic imaging, therapy)
• Humans
• Pancreatic Neoplasms (diagnostic imaging, drug therapy)
• Radiography, Abdominal
• Radiology